Cancer Therapeutics CRC signs agreement to enable Pfizer to develop novel cancer drugs

Melbourne-headquartered Cancer Therapeutics CRC (CTx) today announced a two-year research collaboration and a license agreement with Pfizer Inc.  

Under the terms of the agreement, Pfizer will gain the rights to two novel pre-clinical cancer programs and CTx will receive US$14.2 million [AUD$20M] upfront payment, up to a potential US$460 million [AUD$648M] in development and sales milestones, as well as royalties on product sales if the program reaches commercialization. The two programs target proteins that are known to play an important role in driving the growth of both solid and blood cancers.

Next Section

Finding Cures for Cancer

Our job is to discover promising new small molecule drug compounds and advance them through the high risk early phases of drug development

Backed by business and science expertise


All our discovery projects are managed and scrutinised by a Project Leaders Group and an independent group of experts as part of our CTx Scientific Advisory Group.

Meet our team

Leveraging world class research & technology

Kurt Lackovic

Our research and development platform spans the full range of technologies required to discover small molecule hits and develop them to clinical candidates. Critically, each of our novel drug discovery projects is underpinned by leading medical researchers with cutting edge expertise in the target biology.

Our capabilities

Building a strong pipeline


By providing an integrated and coherent pathway for drug discovery and clinical development, CTx is at the forefront of delivering more effective cancer drugs to market.

See our pipeline

Next Section